We're Here for You!
The IMF is dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure.
I am a...
I am a...
Oncopeptides announced today it is pulling its myeloma drug Pepaxto (melphalan flufenamide) from the market after failing a confirmatory trial. Pepaxto won accelerated approval in February, but in July, the FDA alerted patients and healthcare professionals that the confirmatory trial was halted. Oncopeptides said it will work with the FDA to continue to make Peptaxo available to patients currently receiving the drug.
The tragic loss of former U.S. Secretary of State Colin Powell underscores the importance of booster shots for myeloma patients—and vaccinations for the friends and family members who are in close contact with them.
Register for the October 30th Patient and Family Webinar at 7 a.m. PT / 9 a.m. CT / 10 a.m. ET. It will focus on “Advances in Myeloma Treatments: What Patients & Caregivers Need to Know.” IMF Chairman Dr. Brian G.M. Durie will moderate presentations with IMF Nurse Leadership Board Member Teresa Miceli RN, BSN, OCN (Mayo Clinic — Rochester, MN); Adam Cohen, MD (University of Pennsylvania Perelman School of Medicine — Philadelphia); Paul Richardson, MD (Dana-Farber Cancer Institute — Boston); and IMF Vice President of Support Groups Robin Tuohy. Attendees will learn what the latest advancements in myeloma research mean for patients, how to better manage side effects, optimal choices for relapsed patients, and more.
This past summer, the IMF Nurse Leadership Board (NLB) met to discuss the latest clinical data for cilta-cel, a novel BCMA-targeted CAR-T therapy, in the treatment of patients with multiple myeloma (MM). The NLB identified specific educational needs as they reviewed safety and patient management approaches for CAR-T therapies. Click here to access the publication.
Need to stay informed about the news that impacts myeloma patients, but don’t have time to read everything out there? Then be sure to follow Dr. Brian Durie’s Week in Review blog. The leading myeloma expert and IMF Chairman of the Board drills down on a wide range of topics – from the latest myeloma research results to the environmental issues that offer insight into prevention. He sifts through the data to deliver the bottom line.
Last year marks the International Myeloma Foundation's (IMF) 30th anniversary, celebrating 30 years of scientific achievement with myeloma patient care at the heart of it all. What started in a garage with a borrowed typewriter is now the largest organization focused specifically on multiple myeloma. The IMF continues to push the needle forward toward a cure for myeloma with cure-focused trials and over 40 active research projects around the world. As IMF President and Founder Susie Durie says, "We are this close to the cure. I can see it on the horizon."
The support of loved ones allows us to continue to fund efforts to search for a cure. Check out how Fundraisers are helping in the fight against myeloma.
